Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jul 27, 2026
Why Is Acadia Healthcare Company (ACHC) Stock Up +1.47% Today?

Why Is Acadia Healthcare Company (ACHC) Stock Up +1.47% Today?

Key Takeaways

  • Acadia Healthcare shares gained 1.47% on Friday, closing at $34.51, up $0.50 from the prior session's close of $34.01, extending a remarkable multi-week rally.
  • A wave of analyst price-target increases — including bullish revisions from Guggenheim, KeyBanc, TD Cowen, and UBS — has fueled sustained buying momentum throughout July.
  • Anticipation ahead of Q2 2026 earnings, scheduled for release on Tuesday, July 28, has kept the stock in focus as traders position for the company's next results.
  • The stock is up approximately 143% year-to-date, reflecting a powerful turnaround narrative under returning leadership and improving operational metrics.
  • Elevated short interest — roughly 36.6% of the float — has amplified upward moves as bearish bets face pressure during the rally.
  • Investors now turn their attention to Tuesday's earnings release, where revenue, EPS, and forward guidance will determine whether the rally holds or reverses.

Opening Summary

ACHC — Acadia Healthcare Company, Inc., the largest stand-alone behavioral healthcare provider in the United States — saw its stock rise 1.47% in Friday's trading session. Shares closed at $34.51, adding $0.50 from Thursday's closing price of $34.01. The move marked the latest leg in a sustained rally that has propelled the behavioral health operator's market capitalization to roughly $3.17 billion. Headquartered in Franklin, Tennessee, Acadia operates a network of approximately 275 facilities with roughly 12,400 beds across 40 states and Puerto Rico, providing inpatient psychiatric, substance abuse treatment, and outpatient behavioral health services.

Analyst Upgrades and Price-Target Increases Drive Momentum

A cluster of bullish analyst actions in July has been the primary catalyst behind ACHC's extraordinary run. On July 14, KeyBanc raised its price target to $40 from $30, maintaining an Overweight rating, while TD Cowen lifted its target to $36 from $30 with a Buy rating. Earlier in the month, UBS boosted its target to $39 from $31, and Guggenheim raised its target to $38 from $31. These revisions collectively signal Wall Street's growing conviction that Acadia's turnaround — anchored by returning CEO leadership, bed-capacity expansion, and improved earnings visibility — is gaining real traction. The stock has now blown past the average analyst price target of approximately $32, suggesting the market is pricing in further operational improvements ahead of the company's Q2 report.

Earnings Anticipation Adds Fuel

Acadia Healthcare is scheduled to release its second-quarter 2026 results after the market closes on Tuesday, July 28, with a conference call set for Wednesday, July 29. Analysts are looking for earnings of approximately $0.33 per share on revenue near $848 million, while the company's own guidance calls for EPS in the $0.30–$0.40 range. The company beat expectations handily in Q1, delivering $0.37 per share versus the $0.28 consensus on revenue of $828.8 million — a 7.6% year-over-year increase. That beat, combined with raised full-year guidance for adjusted EBITDA and EPS, set the stage for the current rally. With the earnings event now just one trading day away, positioning flows and anticipation of another potential beat have contributed to Friday's gains.

Turnaround Narrative and Institutional Accumulation

Since the start of 2026, ACHC has undergone a dramatic transformation. The stock entered the year at $14.19 and has surged roughly 143% year-to-date, driven by a combination of new management, cost discipline, and improving facility-level performance. The return of former CEO leadership, the appointment of David Duckworth as Interim CFO, and a strategic focus on boosting underperforming assets have restored investor confidence. Institutional investors have taken note: Principal Financial Group increased its stake by 27.4% in the first quarter, while other large holders — including Wellington Management, Goldman Sachs, and Jefferies Financial Group — have materially expanded their positions. The stock's addition to the Russell 2000 Index after being dropped from the Russell 1000 has also broadened its institutional ownership base.

Market Context and Trading Activity

Friday's session saw roughly 2.3 million shares change hands, modestly below the three-month average volume of approximately 3.1 million. The stock traded in a range of $34.30 to $35.29, briefly testing but not surpassing the 52-week high of $35.83 set earlier in the week. The broader healthcare provider sector has been relatively steady, with peers such as THC and HCA posting solid Q2 results that buoyed sentiment across the group. Acadia's rally has far outpaced both the healthcare sector and the broader S&P 500, reflecting company-specific catalysts rather than a simple sector tailwind. Notably, short interest remains exceptionally elevated at roughly 36.6% of the float — approximately 21.8 million shares — which has amplified upside moves as short sellers face mounting pressure during the stock's relentless ascent.

What Comes Next for ACHC

The immediate focus for ACHC is Tuesday's Q2 earnings release. Beyond the headline numbers, investors will scrutinize same-facility volume trends, bed-ramp progress at newer facilities, margin trajectories, and updated full-year guidance. Key risks include the company's elevated debt load of roughly $2.69 billion, lingering legal overhangs including a $105 million jury verdict against a subsidiary, and the possibility that the rapid share-price appreciation has already priced in optimistic assumptions about the turnaround. On the bullish side, sustained demand for behavioral health services, expanding insurance coverage, and operational improvements under new leadership could extend the rally further. With the stock having more than tripled from its January lows, the Q2 report represents a critical test of whether the fundamentals can justify the extraordinary re-rating.

Trending AI Robots

For traders seeking data-driven strategies in volatile markets like the one ACHC is navigating, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest real-time performance under current market dynamics are featured in this actively maintained section. Bots span a range of strategies, timeframes, and traded symbols, allowing users to identify approaches aligned with their own risk tolerance and market outlook. Explore the Trending AI Robots page to discover which automated strategies are currently outperforming.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ACHC

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


ACHC in upward trend: price expected to rise as it breaks its lower Bollinger Band on July 29, 2026

ACHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where ACHC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where ACHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

ACHC moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHC advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 176 cases where ACHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ACHC moved out of overbought territory on July 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACHC as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ACHC turned negative on July 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.446) is normal, around the industry mean (233.348). P/E Ratio (20.207) is within average values for comparable stocks, (121.392). ACHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.749). ACHC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (0.827) is also within normal values, averaging (2.620).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.72B. The market cap for tickers in the group ranges from 48.5K to 88.53B. HCA holds the highest valuation in this group at 88.53B. The lowest valued company is BYZN at 48.5K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 34%. WW experienced the highest price growth at 21%, while NIVF experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was 29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 49
Price Growth Rating: 49
SMR Rating: 66
Profit Risk Rating: 89
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
ACHC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of a network of behavioral health centers

Industry HospitalNursingManagement

Profile
Details
Industry
Medical Or Nursing Services
Address
4020 Aspen Grove Drive
Phone
+1 615 861-6000
Employees
25000
Web
https://www.acadiahealthcare.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.